II. The Present Position of the Surgery of the Hypertrophied Prostate

Androgenuria Nel Cancro Della Prostata

The excretion of urinary androgen has been determined in 21 cases of prostatic cancer before and after therapy with diethylstilbestrol. A considerable reduction was observed, thus showing that the hormonal therapy had reached the main scope of diminishing the androgenic production of the organism.

Leuprorelin depot injection: patient considerations in the management of prostatic cancer

Hormone therapy is well established for treating patients with prostate cancer and remains the mainstay of the treatment of metastatic and locally advanced disease, this article reviews the rationale for its use, its different forms, and complications and controversies still surrounding some of its modalities. Availability of long-acting synthetic luteinizing hormone-releasing hormone (LHRH) agonists revolutionized the hormonal treatment of prostate cancer, and helped to avoid the emotional and psychological effects related to surgical castration. The depot formula has gained wide acceptance from both patients and physicians. This review emphasizes the newer, long-acting formula, leuprorelin (leuprolide acetate), especially the 6-month formula, its advantage over over shorter-acting depot products, and its potential to become a standard of care for patients eligible for androgen deprivation therapy.